Adial Pharmaceuticals, Inc
ADILAdial Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for addiction and other neurological disorders. The company’s main product candidate is aimed at treating alcohol use disorder by targeting specific neurological pathways. Adial aims to provide effective treatments for addiction-related conditions through innovative pharmacological approaches.
Company News
Adial Pharmaceuticals announced the publication of an international patent application for AD04, its lead investigational drug for treating Alcohol Use Disorder in heavy drinking patients. The patent, once granted, is expected to protect the company's core assets through at least 2045. The patent application is based on treatment of populations i...
Adial Pharmaceuticals' CEO Cary Claiborne was featured on the Big Biz Show, discussing the company's clinical-stage biopharmaceutical work in addiction treatment, specifically highlighting their investigational drug AD04 for Alcohol Use Disorder.
The substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.
Adial Pharmaceuticals received positive feedback from the FDA on its proposed in vitro bridging strategy for its drug candidate AD04, a key step towards advancing the drug into Phase 3 clinical trials for the treatment of alcohol use disorder.
Adial Pharmaceuticals announced positive results from a pharmacokinetics study of its investigational drug AD04 for the treatment of Alcohol Use Disorder. The study results support the planned near micro-dosing regimen and the company's plans to pursue FDA approval under the 505(b)(2) regulatory pathway.
